Top cited articles

Acceptance Rate


Time to first decision

8 days*

Time from acceptance to publication

13 days*

Impact Factor (JCR):


Impact Factor rank (JCR):




Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco, Milena; Hyrich, Kimme L.; Al-Adely, Sarah et al

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Smolen, Josef S.; Landewe, Robert B. M.; Bijlsma, Johannes W. J. et al

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, Antonis; Kostopoulou, Myrto; Alunno, Alessia et al

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Monti, Sara; Balduzzi, Silvia; Delvino, Paolo et al

EULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, Maria G.; Andreoli, Laura; Limper, Marteen et al

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort
Pouletty, Marie; Borocco, Charlotte; Ouldali, Naim

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Furer, Victoria; Rondaan, Christien; Heijstek, Marloes W. et al

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Aringer, Martin; Costenbader, Karen; Daikh, David et al

2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Hellmich, Bernhard; Agueda, Ana; Monti, Sara et al

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
Mathian, Alexis; Mahevas, Matthieu; Rohmer, Julien

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2
Landewe, Robert B. M.; Machado, Pedro M.; Kroon, Feline et al

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Della-Torre, Emanuel; Campochiaro, Corrado; Cavalli, Giulio

Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
Pablos, Jose L.; Galindo, Maria; Carmona, Loreto

Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017
Safiri, Saeid; Kolahi, Ali Asghar; Hoy, Damian

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
Rosenzwajg, Michelle; Lorenzon, Roberta; Cacoub, Patrice et al

Classification criteria for autoinflammatory recurrent fevers
Gattorno, Marco; Hofer, Michael; Federici, Silvia

CircSERPINE2 protects against osteoarthritis by targeting miR-1271 and ETS-related gene
Shen, Shuying; Wu, Yizheng; Chen, Junxin

Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective
Damoiseaux, Jan; Coelho Andrade, Luis Eduardo; Gabriel Carballo, Orlando et al

Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts
Wallace, Zachary S.; Zhang, Yuqing; Perugino, Cory A. et al

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Schreiber, Stefan; Colombel, Jean-Frederic; Feagan, Brian G. et al